These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36498627)

  • 1. Preliminary Study of Different Treatment Responses between Bevacizumab, Aflibercept and Dexamethasone Implant According to Renal Function in Diabetic Macular Edema Patients.
    Moon TH; Jo GH; Seo EJ; Kim KT; Ku EJ; Kwon SK; Kim JY; Chae JB; Kim DY
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SYSTEMIC FACTORS AND EARLY TREATMENT RESPONSE TO INTRAVITREAL INJECTION FOR DIABETIC MACULAR EDEMA: The Role of Renal Function.
    Hwang H; Lee H; Kim JY; Lee S; Seo EJ; Chae JB; Kim DY
    Retina; 2021 Jun; 41(6):1275-1282. PubMed ID: 33141788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the short-term effect of aflibercept and dexamethasone implant on serous retinal detachment in the treatment of naive diabetic macular edema.
    Bolukbasi S; Cakir A; Erden B; Karaca G
    Cutan Ocul Toxicol; 2019 Dec; 38(4):401-405. PubMed ID: 31438736
    [No Abstract]   [Full Text] [Related]  

  • 4. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders.
    Salimi A; Vila N; Modabber M; Kapusta M
    Indian J Ophthalmol; 2021 Feb; 69(2):360-367. PubMed ID: 33463593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
    Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
    JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early efficacy of dexamethasone implant (OZURDEX
    Sarda V; Fajnkuchen F; Nghiem-Buffet S; Grenet T; Chaine G; Giocanti-Auregan A
    J Fr Ophtalmol; 2017 May; 40(5):408-413. PubMed ID: 28336283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.
    Ozsaygili C; Duru N
    Retina; 2020 Jun; 40(6):1044-1052. PubMed ID: 30950970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
    Hwang HS; Chae JB; Kim JY; Kim DY
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5958-5967. PubMed ID: 29183041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dril Influences Short-term Visual Outcome after Intravitreal Corticosteroid Injection for Refractory Diabetic Macular Edema.
    Luís ME; Sampaio F; Costa J; Cabral D; Teixeira C; Ferreira JT
    Curr Eye Res; 2021 Sep; 46(9):1378-1386. PubMed ID: 33463388
    [No Abstract]   [Full Text] [Related]  

  • 12. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.
    Nikkhah H; Niazpour Moez R; Entezari M; Ramezani A; Hassanpour K; Karimi S; Yaseri M
    Graefes Arch Clin Exp Ophthalmol; 2021 Oct; 259(10):2949-2959. PubMed ID: 33856549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema.
    Klein KA; Cleary TS; Reichel E
    Int J Retina Vitreous; 2017; 3():16. PubMed ID: 28373914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks.
    Hernández-Bel L; Cervera-Taulet E; Navarro-Palop C; Castro-Navarro V; Chiarri-Toumit C; Montero-Hernández J
    Ophthalmologica; 2019; 241(2):98-104. PubMed ID: 29996128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.
    Tran THC; Erginay A; Verdun S; Fourmaux E; Le Rouic JF; Uzzan J; Milazzo S; Baillif S; Kodjikian L
    Clin Ophthalmol; 2021; 15():1971-1978. PubMed ID: 34007150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of the efficacy of early switching from bevacizumab to aflibercept or ranibizumab in diabetic macular edema.
    Ataş M; Ozsaygılı C; Bayram N; Unal S
    Eur J Ophthalmol; 2022 Nov; ():11206721221137164. PubMed ID: 36330651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.